Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals (Q36254302)

13 August 2017

1 reference

title

Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals (English)

1 reference

13 August 2017

1 reference

Marilyn Martinez

1

1 reference

PubMed ID

16154368

13 August 2017

Patrick McDermott

series ordinal

2

1 reference

PubMed ID

16154368

13 August 2017

Robert Walker

series ordinal

3

1 reference

13 August 2017

9 September 2005

1 reference

13 August 2017

The Veterinary Journal

1 reference

13 August 2017

172

1 reference

13 August 2017

10-28

1 reference

13 August 2017

1

1 reference

Studies of ion-exchange resin complex of chloroquine phosphate

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Taste masking of diclofenac sodium using microencapsulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The mar regulon: multiple resistance to antibiotics and other toxic chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The fluoroquinolone antibacterials: past, present and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Application of muscle microdialysis to evaluate the concentrations of the fluoroquinolones pazufloxacin and ofloxacin in the tissue interstitial fluids of rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Quinolone generations: natural history or natural selection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Evaluation of electrophoretic method versus chromatographic, potentiometric and absorptiometric methodologies for determing pK(a) values of quinolones in hydroorganic mixtures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Electrophoretic behaviour of quinolones in capillary electrophoresis. Effect of pH and evaluation of ionization constants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Prediction of electrophoretic behaviour of a series of quinolones in aqueous methanol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Clinical role of protein binding of quinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The safety profile of the fluoroquinolones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Expanded activity and utility of the new fluoroquinolones: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Intracellular concentrations of antibacterial agents and related clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The influence of film coating on pellet properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Trends in fluoroquinolone resistance of bacteria isolated from canine urinary tracts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

A multidrug resistance regulatory chromosomal locus is widespread among enteric bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Bacterial biofilms: a common cause of persistent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetics of ibafloxacin in healthy cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

QT Prolongation and Fatal Arrhythmias: A Review of Clinical Implications and Effects of Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Fluoroquinolones: action and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Effect of food and gastric pH on the bioavailability of grepafloxacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Structure-absorption relationships of a series of 6-fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Effect of a high-fat meal on the pharmacokinetics of the des-F(6)-quinolone BMS-284756.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Mechanisms of quinolone action and microbial response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Fluoroquinolone resistance among Gram-positive cocci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Prevalence of plasmid-mediated quinolone resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Effects of food on the pharmacokinetics of sparfloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Topoisomerase IV is a target of quinolones in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Physicochemical properties of enrofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamics of fluoroquinolones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Long depletion time of enrofloxacin in rainbow trout (Oncorhynchus mykiss).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Application of preclinical data to initiate the modified continual reassessment method for maximum tolerated dose-finding trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Quinolone resistance from a transferable plasmid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

A study of metabolites isolated from the urine samples of cats and dogs administered orbifloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetics and tissue disposition of danofloxacin in sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Impact of pharmacodynamics on breakpoint selection for susceptibility testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Penetration of moxifloxacin into peripheral compartments in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamics and pharmacokinetics of levofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Enantioselective disposition of ofloxacin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Torsades de pointes associated with fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Optimal use of modern antibiotics: emerging trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Drug-drug interactions with ciprofloxacin and other fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Absorption of ofloxacin isomers in the rat small intestine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Toxicity of fluoroquinolone antibiotics to aquatic organisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetics and pharmacodynamics of fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Prediction of retention behaviour and evaluation of pka values of peptides and quinolones in liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetics of enrofloxacin in neonatal kittens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

High-performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Mechanism of plasmid-mediated quinolone resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Quinolones in 2005: an update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Rapid selection of quinolone resistance in Campylobacter jejuni but not in Escherichia coli in individually housed broilers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Antimicrobial treatment of prostatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The use of fluoroquinolones for companion animal antimicrobial therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Mechanisms of fluoroquinolone transport by human neutrophils.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Simultaneous determination of total body water and plasma volume in conscious dogs by the indicator dilution principle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Pharmacokinetic behavior of marbofloxacin after intravenous and intramuscular administrations in adult goats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Application of fluoroquinolone pharmacodynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

The effect of enrofloxacin on cell proliferation and proteoglycans in horse tendon cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Quinolone-resistant mutations of the gyrA gene of Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.07.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TVJL.2005.07.010

1 reference

13 August 2017

1 reference

PubMed ID

16154368